This paper provides a comprehensive overview of colon cancer, the third most common cancer in the United States. It examines the molecular and cellular pathophysiology underlying adenocarcinoma development, including chromosomal deletions, tumor suppressor mutations, and hereditary conditions such as HNPCC. The paper outlines major risk factors—including age, diet, and hormonal status—before explaining the Dukes classification system and its relationship to five-year survival rates. It then surveys current medical and surgical treatment strategies, including combination chemotherapy regimens such as the Saltz regimen, intrahepatic arterial chemotherapy with FUDR, adjuvant therapy for stage C disease, and resection techniques including laparoscopic and partial hepatectomy approaches.
The paper demonstrates effective use of source-integrated evidence. Rather than simply listing facts, it attributes specific findings to named studies and authors (e.g., "Both a European trial and a U.S. trial found…"), which grounds clinical claims in the research literature and models proper citation practice in a health sciences context.
The paper opens with an epidemiological introduction establishing prevalence and treatability. It proceeds through five clearly labeled sections: pathophysiology (molecular mechanisms), risk factors (lifestyle and demographic variables), staging classifications (Dukes system with survival statistics), medical care (chemotherapy, adjuvant therapy, and surgical options), and a brief summary reinforcing the importance of early detection. The structure moves from cause to consequence to intervention, a classic expository pattern in medical writing.
Colon cancer is the third most common cancer in men and women in the United States (Cappell, 2005). It is often curable by surgery if detected early. Systemic and regional chemotherapy are frequently used in the treatment of patients with metastatic colon cancer. Radiotherapy is used in cases of rectal cancer to reduce the risk of local recurrence. Long-term survival is closely related to the stage of disease at diagnosis. Efforts are underway to develop better screening strategies and novel therapies to improve patient survival rates and to minimize toxicity.
The majority of colon cancers are adenocarcinomas (Buda & Pignatelli, 2004). Chromosome arm 18q deletions are a later event associated with cancer development; these deletions typically involve the targets DPC4 and DCC. Chromosome arm 17p losses and tumor suppressor p53 mutations are common events in late-stage colon cancer. Bcl-2 overexpression, which leads to inhibition of cell death signaling, has been observed as a relatively early event in colon cancer development.
Another predisposing condition is hereditary nonpolyposis colon cancer (HNPCC), in which individuals inherit a mutation in one of several genes involved in DNA mismatch repair, including MSH2, MLH1, and PMS2 (Guimbaud & Selves, 2003).
Several risk factors have been associated with colon cancer. Colonic polyps, which occur with increasing age, represent a significant risk for colon cancer development (Kronborg, 2004). Increasing age and lower intake of folate have been associated with mutations of the Ki-ras oncogene, which are found commonly in colon cancer. Fat content of the diet has also been associated with an increased risk of colon cancer.
Weak evidence suggests that soy food or isoflavones in the diet may protect against colon cancer. Exercise is believed to reduce the risk of colon cancer. Postmenopausal women who have never used hormone replacement therapy have a higher risk of colon cancer — though not rectal cancer — compared to premenopausal women of the same age, sociocultural class, and dietary habits. No association has been established between frequency of bowel movement or laxative use and risk of colon cancer.
You’re 27% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.